|Bid||0.00 x 3200|
|Ask||0.00 x 3000|
|Day's Range||6.16 - 6.65|
|52 Week Range||6.16 - 157.98|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 28, 2022 - Mar. 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.20|
In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Allakos published phase 3 Enigma 2 and phase 2/3 Kryptos trial data on its lirentelimab monoclonal antibody as a treatment for eosinophilic gastrointestinal diseases (EGIDs), and the results shocked the market. Lirentelimab had shown promising results as a treatment for eosinophilic gastrointestinal diseases in its phase 2 trials, and the phase 3 data caught the market off guard. The crushing study results were followed by a series of downgrades from high-profile analysts.